COMPANY
Meet our team

Thierry Burnouf is distinguished Professor and Vice-Dean at College of Biomedical Engineering, Taipei Medical University, Taiwan, and Honorary Professor at University of Lille, France.

He is a world-recognized expert in plasma and platelet bioprocessing with a track record that directly supports Invenis Biotherapies’ clinical and commercial roadmap. He has spent more than three decades developing scalable, regulator-compatible processes for plasma derived medicinal products technologies now central to much of the modern foundation for human platelet lysates, platelet extracellular vesicles entering the regenerative medicine and neurodegeneration fields.

He has authored 350+ peer-reviewed publications, is the inventor of 25+ patent families, and has secured substantial national and international funding to advance platelet-derived biotherapies from concept to preclinical validation. His technologies for platelet lysate processing, viral safety, and EV purification has won competitive research funding secured across Taiwanese and European programs (NSTC, NHRI, EuroNanoMed) and underpin preclinical development programs led by Invenis Biotherapies.

Prof. Burnouf plays a central role in global blood safety policy and cell therapies through the International Society of Blood Transfusion (ISBT) and acts as an advisor to the World Health Organization on improving on quality, safety and access to safe plasma-derived medicinal products in emerging markets. His work accelerates regulatory acceptance and de-risks manufacturing pathways for next-generation biologics, and directly supports Invenis Biotherapies’ competitive positioning through strong IP defensibility, manufacturing readiness, and clear regulatory pathways for platelet-derived neurotherapeutics.

His scientific and industrial contributions have been recognized through major distinctions, including the 2019 IPFA Award for Excellence in Plasma Fractionation, the 2021 NSTC Outstanding Research Award, the 2024 ISBT Presidential Award, and the Taiwan 2024 Executive Yuan Award for Outstanding Science and Technology Contribution for his research on blood products.

At Taipei Medical University, he leads a multidisciplinary program developing platelet-derived secretome therapies for neurodegenerative diseases, aging, and CNS repair, with strong clinical and academic partnerships. His expertise helps guide Invenis Biotherapies in building robust, scalable, and regulator-ready manufacturing strategies for innovative platelet-based therapeutics.

Caroline Moreau, professor of neurology at the Lille University Hospital in France, has co-authored 103 professional publications in the field of Neuroscience and clinical neurology, 5 patents and 2 industrial transfers. She participated in 34 studies including 18 multi-center trials.

She focused her research on axial disorders in neurodegenerative diseases, namely Parkinsonian syndromes and especially Parkinson’s disease.  She studied pathophysiology of axial disorders in PD and its natural history (3 grants), therapeutical aspects (2 grants) and compensatory mechanisms. Her work is recognized internationally in the field of speech and gait disorders, by participating in the MDS dysarthria task force, MDS task force for postural deformities and IC FOG consortium, Mickael J Fox Foundation task force for gait disorders. Another part of her clinical research is dedicated to innovative therapeutics in the field of Parkinson’s disease : she is co-PI of the H2020 Fair Park 2 study and PI of the Intra ventricular dopamine infusion strategy for severe motor fluctuations in people with parkinson’s disease. She is Chief Medical Officer of InBrain Pharma since 2018, Medical Advisor of InVenis Biotherapies since 2022, and FEET ME since 2022.

She is associated editor of journal of Parkinson’s disease since 2019. She is member of the EAN assembly of delegates for France since 2016; EAN scientific program committee since.

David Devos is Professor of Medical Pharmacology, Neurologist at the University of Lille, Inserm and University Hospital of Lille.
His main domain of research concerns development of innovative therapeutic strategies in neurodegenerative diseases from the concept through in vitro and in vivo research to large phase clinical trials.
He participated in over 450 publications including more than 300 papers, conducted 35 clinical studies including 15 multi-centre trials, 14 as coordinator, 4 European Commission funded projects (H2020); career competitive research funding > 20M€
He is consultant and running research at the expert center of Parkinson’s disease (PD) and Amyotrophic Lateral Sclerosis (ALS) of Lille. He is co-coordinating the French network of PD (NS-Park-F-CRIN) and of ALS (ACT4ALS-MND) and is involved for the research in Lille national referent Expert centers for PD and ALS with large cohorts of patients.

He obtained several awards: the European Pharmacology Prize, the French Medical Pharmacology Prize, Price of the stars of Europe, Price of the stars of the North of France, European Innovation Award from the European Patent Office, National Academy of Medicine Award: Aimée and Raymond Mande Award, Official selection for the prestigious Galien Price, Appointment to the University Institute of France as Chair of Innovation by the Minister of National Education, Higher Education, and Research.

Dr. Penn is a neurosurgeon who has been involved in translational medicine for movement disorders his whole career. He implanted the first drug pump for pain in 1982 and two years later pioneered in the use of intrathecal baclofen for severe spasticity. Over 150,000 patients have had or are now currently receiving this treatment in the US. With the Movement Disorder Center at Rush he investigated transplants for Parkinson’s disease and Huntington’s and had an active functional neurosurgical practice treating movement disorders with lesions and DBS. He served on the FDA advisory committee for neurological drugs for six years and has worked on several of his own individual INDs. In addition, he was the first to investigate intrathecal neurotrophin infusions for the treatment of ALS. He was part of the Amgen GDNF trial for Parkinson’s disease. With engineers at the University of Illinois Chicago, he developed new MRI techniques to model the distribution of IT infusion of medications. As a clinical investigator he has worked with multiple pharmaceutical companies and device manufacturers. In 2007 he co-founded CNS Therapeutics, a company that develops medications for IT use. Currently he is president of NTF Therapeutics.

Dr. Penn brings a rare combination of clinical domain authority, regulatory experience, device and drug development expertise, and a history of pioneering CNS therapies from concept through FDA approval and widespread adoption.